Literature DB >> 11727828

The MKK6/p38 mitogen-activated protein kinase pathway is capable of inducing SOCS3 gene expression and inhibits IL-6-induced transcription.

J G Bode1, S Ludwig, C A Freitas, F Schaper, M Ruhl, S Melmed, P C Heinrich, D Häussinger.   

Abstract

In this study we show that activation of p38MAPK by IL-6 acts as an inhibitory signal on IL-6-mediated activation of STAT and the alpha2-macroglobulin promoter. We analyzed the role of MKK6/p38MAPK for IL-6 signal transduction and transcriptional activation of the suppressor of cytokine signaling (SOCS) 3 promoter. Pretreatment of cells with the p38MAPK-specific inhibitor SB202190 downregulates the induction of SOCS3-mRNA expression by IL-6. Accordingly, overexpression of a constitutively active MKK6 in HepG2 cells enhanced basal activity or IL-6-induced transcriptional activation of a SOCS3 promoter reporter construct, whereas overexpression of a dominant negative mutant of MKK6 downregulated the IL-6-mediated activation of the SOCS3 promoter. These data indicate that p38MAPK-activation is crucial for IL-6-induced SOCS3 expression and downregulation of IL-6-mediated gene induction.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11727828     DOI: 10.1515/BC.2001.178

Source DB:  PubMed          Journal:  Biol Chem        ISSN: 1431-6730            Impact factor:   3.915


  21 in total

1.  Peginesatide and erythropoietin stimulate similar erythropoietin receptor-mediated signal transduction and gene induction events.

Authors:  Jennifer M Green; Karen Leu; Angela Worth; Richard B Mortensen; David K Martinez; Peter J Schatz; Don M Wojchowski; Peter R Young
Journal:  Exp Hematol       Date:  2012-03-06       Impact factor: 3.084

2.  Galectins regulate the inflammatory response in airway epithelial cells exposed to microbial neuraminidase by modulating the expression of SOCS1 and RIG1.

Authors:  Mihai Nita-Lazar; Aditi Banerjee; Chiguang Feng; Gerardo R Vasta
Journal:  Mol Immunol       Date:  2015-09-06       Impact factor: 4.407

3.  Dysregulation of janus kinases and signal transducers and activators of transcription in cancer.

Authors:  Ana P Costa-Pereira; Nair A Bonito; Michael J Seckl
Journal:  Am J Cancer Res       Date:  2011-06-22       Impact factor: 6.166

Review 4.  SOCS3 revisited: a broad regulator of disease, now ready for therapeutic use?

Authors:  R Mahony; S Ahmed; C Diskin; N J Stevenson
Journal:  Cell Mol Life Sci       Date:  2016-05-02       Impact factor: 9.261

Review 5.  Cross-regulation of signaling by ITAM-associated receptors.

Authors:  Lionel B Ivashkiv
Journal:  Nat Immunol       Date:  2009-03-19       Impact factor: 25.606

6.  Rhinovirus-Induced SIRT-1 via TLR2 Regulates Subsequent Type I and Type III IFN Responses in Airway Epithelial Cells.

Authors:  Nathaniel Xander; Hymavathi Reddy Vari; Rewees Eskandar; Wuyan Li; Sudhir Bolla; Nathaniel Marchetti; Umadevi S Sajjan
Journal:  J Immunol       Date:  2019-09-23       Impact factor: 5.422

Review 7.  Principles of interleukin (IL)-6-type cytokine signalling and its regulation.

Authors:  Peter C Heinrich; Iris Behrmann; Serge Haan; Heike M Hermanns; Gerhard Müller-Newen; Fred Schaper
Journal:  Biochem J       Date:  2003-08-15       Impact factor: 3.857

8.  Extra-hepatic cancer represses hepatic drug metabolism via interleukin (IL)-6 signalling.

Authors:  Marina Kacevska; Andre Mahns; Rohini Sharma; Stephen J Clarke; Graham R Robertson; Christopher Liddle
Journal:  Pharm Res       Date:  2013-04-20       Impact factor: 4.200

9.  CD14 signaling restrains chronic inflammation through induction of p38-MAPK/SOCS-dependent tolerance.

Authors:  Bikash Sahay; Rebeca L Patsey; Christian H Eggers; Juan C Salazar; Justin D Radolf; Timothy J Sellati
Journal:  PLoS Pathog       Date:  2009-12-11       Impact factor: 6.823

10.  Abrogation of IL-6-mediated JAK signalling by the cyclopentenone prostaglandin 15d-PGJ(2) in oral squamous carcinoma cells.

Authors:  H Siavash; N G Nikitakis; J J Sauk
Journal:  Br J Cancer       Date:  2004-09-13       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.